Spyre Therapeutics, Inc.
$73.39
▼
-2.7%
2026-04-21 09:42:01
www.spyre.com
NMS: SYRE
Explore Spyre Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.76 B
Current Price
$73.39
52W High / Low
$75 / $12.25
Stock P/E
—
Book Value
$7.16
Dividend Yield
—
ROCE
-30.53%
ROE
-25.17%
Face Value
—
EPS
$-1.98
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
102
Beta
2.94
Debt / Equity
—
Current Ratio
13.25
Quick Ratio
13.25
Forward P/E
-17.13
Price / Sales
—
Enterprise Value
$3.43 B
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$64.36
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 2. | Heron Therapeutics, Inc. | $1.05 | — | $187.09 M | — | -1.59% | 209.08% | $2.61 / $0.74 | $0.07 |
| 3. | Inovio Pharmaceuticals, Inc. | $1.18 | — | $96.69 M | — | -283.35% | -1.83% | $2.98 / $1.03 | $0.35 |
| 4. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 5. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 6. | Kyntra Bio, Inc. | $7.34 | 0.16 | $29.62 M | — | -50.18% | -143.52% | $12.6 / $4.85 | $-7.42 |
| 7. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -57.17 M | -56.89 M | -51.94 M | -53.57 M | -61.25 M | — |
| Net Profit | -62.53 M | -11.18 M | -36.72 M | -44.77 M | -56.3 M | — |
| EPS in Rs | -0.8 | -0.14 | -0.47 | -0.57 | -0.72 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.89 M | 2.33 M |
| Operating Profit | -219.56 M | -208.57 M | -128.56 M | -84.78 M |
| Net Profit | -155.2 M | -208.02 M | -338.79 M | -83.81 M |
| EPS in Rs | -1.98 | -2.65 | -4.31 | -1.07 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 777.78 M | 608.48 M | 341.86 M | 71.14 M |
| Total Liabilities | 62.55 M | 90.68 M | 157.84 M | 20.84 M |
| Equity | 715.24 M | 517.8 M | 184.02 M | 50.3 M |
| Current Assets | 777.78 M | 608.47 M | 341.53 M | 62.26 M |
| Current Liabilities | 58.69 M | 54.06 M | 31.98 M | 14.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -169.25 M | -157.41 M | -99.91 M | -80.14 M |
| Investing CF | -143.47 M | -353.29 M | -108.39 M | 57.01 M |
| Financing CF | 309.02 M | 410.91 M | 361.08 M | 42.68 M |
| Free CF | -169.25 M | -157.41 M | -99.91 M | -80.18 M |
| Capex | — | — | — | -0.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | -61.96% | — |
| Earnings Growth % | 25.39% | 38.6% | -304.21% | — |
| Profit Margin % | — | — | -38238.15% | -3598.75% |
| Operating Margin % | — | — | -14510.61% | -3640.23% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -14426.64% | -3555.9% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-09-08 | 1:0.04 |